PT1399143E - Utilização da acetil-l-carnitina na preparação de um medicamento para tratar a anedonia - Google Patents
Utilização da acetil-l-carnitina na preparação de um medicamento para tratar a anedonia Download PDFInfo
- Publication number
- PT1399143E PT1399143E PT02741156T PT02741156T PT1399143E PT 1399143 E PT1399143 E PT 1399143E PT 02741156 T PT02741156 T PT 02741156T PT 02741156 T PT02741156 T PT 02741156T PT 1399143 E PT1399143 E PT 1399143E
- Authority
- PT
- Portugal
- Prior art keywords
- stress
- carnitine
- acetyl
- quot
- mice
- Prior art date
Links
- 208000007415 Anhedonia Diseases 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 title claims description 73
- 229940079593 drug Drugs 0.000 title description 8
- 238000011282 treatment Methods 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- -1 alkanoyl L-carnitine Chemical compound 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims description 16
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-M 2-aminoethanesulfonate Chemical compound NCCS([O-])(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-M 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims description 2
- 235000002538 magnesium citrate Nutrition 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 229940095060 magnesium tartrate Drugs 0.000 claims description 2
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims description 2
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 claims description 2
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 claims description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 229960004203 carnitine Drugs 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 229960001367 tartaric acid Drugs 0.000 claims 1
- 230000035882 stress Effects 0.000 description 71
- 241000699670 Mus sp. Species 0.000 description 60
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 54
- 230000037326 chronic stress Effects 0.000 description 44
- 241001465754 Metazoa Species 0.000 description 33
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 31
- 229960004801 imipramine Drugs 0.000 description 31
- 230000000694 effects Effects 0.000 description 29
- 229960003638 dopamine Drugs 0.000 description 27
- 238000012360 testing method Methods 0.000 description 21
- 238000012549 training Methods 0.000 description 20
- 235000009499 Vanilla fragrans Nutrition 0.000 description 17
- 244000263375 Vanilla tahitensis Species 0.000 description 17
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 17
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 16
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 15
- 229960002464 fluoxetine Drugs 0.000 description 15
- 238000000034 method Methods 0.000 description 11
- 239000008188 pellet Substances 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229960003920 cocaine Drugs 0.000 description 8
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 5
- 230000003042 antagnostic effect Effects 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 210000001009 nucleus accumben Anatomy 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 239000000385 dialysis solution Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 210000002442 prefrontal cortex Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000292A ITRM20010292A1 (it) | 2001-05-29 | 2001-05-29 | Uso dell'acetil l-carnitina per la preparazione di un medicamento peril trattamento dell'anedonia. |
| IT2001RM000319A ITRM20010319A1 (it) | 2001-06-08 | 2001-06-08 | Uso di una alcanoil l-carnitina per la preparazione di un medicamentoper il trattamento dell'anedonia. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1399143E true PT1399143E (pt) | 2007-01-31 |
Family
ID=26332845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02741156T PT1399143E (pt) | 2001-05-29 | 2002-05-24 | Utilização da acetil-l-carnitina na preparação de um medicamento para tratar a anedonia |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20040171685A1 (enExample) |
| EP (1) | EP1399143B1 (enExample) |
| JP (1) | JP2004532867A (enExample) |
| KR (1) | KR20040003031A (enExample) |
| AT (1) | ATE345124T1 (enExample) |
| CA (1) | CA2448246A1 (enExample) |
| CZ (1) | CZ20033222A3 (enExample) |
| DE (1) | DE60216090T2 (enExample) |
| DK (1) | DK1399143T3 (enExample) |
| ES (1) | ES2275881T3 (enExample) |
| HU (1) | HUP0400007A2 (enExample) |
| MX (1) | MXPA03010920A (enExample) |
| PL (1) | PL367628A1 (enExample) |
| PT (1) | PT1399143E (enExample) |
| SK (1) | SK15862003A3 (enExample) |
| WO (1) | WO2002096411A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20020620A1 (it) * | 2002-12-13 | 2004-06-14 | Sigma Tau Ind Farmaceuti | Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa. |
| CA3238205A1 (en) | 2021-11-12 | 2023-05-19 | Rajaram Samant | A synergistic composition for activating intracellular secondary messenger(camp) pathway |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4346107A (en) * | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
| IT1291930B1 (it) * | 1997-06-18 | 1999-01-21 | Sigma Tau Ind Farmaceuti | Composizione riequilibratrice delle turbe dell'umore in individui sani |
-
2002
- 2002-05-24 DE DE60216090T patent/DE60216090T2/de not_active Expired - Fee Related
- 2002-05-24 EP EP02741156A patent/EP1399143B1/en not_active Expired - Lifetime
- 2002-05-24 ES ES02741156T patent/ES2275881T3/es not_active Expired - Lifetime
- 2002-05-24 CA CA002448246A patent/CA2448246A1/en not_active Abandoned
- 2002-05-24 WO PCT/IT2002/000339 patent/WO2002096411A1/en not_active Ceased
- 2002-05-24 US US10/478,998 patent/US20040171685A1/en not_active Abandoned
- 2002-05-24 AT AT02741156T patent/ATE345124T1/de not_active IP Right Cessation
- 2002-05-24 KR KR10-2003-7015576A patent/KR20040003031A/ko not_active Ceased
- 2002-05-24 PT PT02741156T patent/PT1399143E/pt unknown
- 2002-05-24 PL PL02367628A patent/PL367628A1/xx unknown
- 2002-05-24 DK DK02741156T patent/DK1399143T3/da active
- 2002-05-24 HU HU0400007A patent/HUP0400007A2/hu unknown
- 2002-05-24 JP JP2002592921A patent/JP2004532867A/ja active Pending
- 2002-05-24 MX MXPA03010920A patent/MXPA03010920A/es active IP Right Grant
- 2002-05-24 SK SK1586-2003A patent/SK15862003A3/sk unknown
- 2002-05-24 CZ CZ20033222A patent/CZ20033222A3/cs unknown
-
2005
- 2005-12-20 US US11/311,406 patent/US20060148896A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60216090T2 (de) | 2007-05-31 |
| JP2004532867A (ja) | 2004-10-28 |
| CZ20033222A3 (cs) | 2004-06-16 |
| DE60216090D1 (de) | 2006-12-28 |
| WO2002096411A1 (en) | 2002-12-05 |
| SK15862003A3 (sk) | 2004-06-08 |
| KR20040003031A (ko) | 2004-01-07 |
| US20040171685A1 (en) | 2004-09-02 |
| ES2275881T3 (es) | 2007-06-16 |
| HUP0400007A2 (hu) | 2004-04-28 |
| CA2448246A1 (en) | 2002-12-05 |
| PL367628A1 (en) | 2005-03-07 |
| EP1399143A1 (en) | 2004-03-24 |
| EP1399143B1 (en) | 2006-11-15 |
| ATE345124T1 (de) | 2006-12-15 |
| US20060148896A1 (en) | 2006-07-06 |
| DK1399143T3 (da) | 2007-03-26 |
| MXPA03010920A (es) | 2004-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6335361B1 (en) | Method of treating benign forgetfulness | |
| PT1463528E (pt) | Inibidores selectivos da recaptação da serotonina e da norepinefrina para tratamento de síndrome de fibromialgia, síndrome da fadiga crónica e dor | |
| Rollinson et al. | Postanoxic action myoclonus (Lance-Adams syndrome) responding to valproate | |
| JP2003171271A (ja) | 耐糖能異常用薬剤 | |
| PT1399143E (pt) | Utilização da acetil-l-carnitina na preparação de um medicamento para tratar a anedonia | |
| US5001117A (en) | Use of lecithin to restore olfaction and taste | |
| Lappa et al. | Successful treatment of a complicated case of neuroleptic malignant syndrome | |
| JP2005523269A (ja) | 老人性うつ病の治療におけるカルニチン | |
| JP2011116775A (ja) | 局所脳血流低下に伴う神経系障害の予防または治療のための医薬組成物 | |
| Sanap et al. | Neurologic complications of critical illness: part I. Altered states of consciousness and metabolic encephalopathies | |
| Rubin et al. | Reversible akinetic mutism possibly induced by baclofen | |
| CA2585560C (en) | Use of acetyl l-carnitine for the treatment of fibromyalgic syndrome | |
| BR112021005193A2 (pt) | medicamento e combinação para a prevenção, alívio ou tratamento de transtorno de estresse agudo ou transtorno de estresse pós-traumático, e, medicamento para a prevenção, alívio ou tratamento de sintoma de transtorno de estresse pós-traumático | |
| Losowsky et al. | Hepatic encephalopathy | |
| ES2425045T3 (es) | Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa | |
| JPH0826987A (ja) | アシルカルニチン含有製剤 | |
| JP2005015417A (ja) | 抗疲労組成物 | |
| Nayak et al. | Effectiveness of L-ornithine L-aspartate in the management of hepatic encephalopathy | |
| WO2002087561A1 (en) | Method of treating age-related vision impairment | |
| Meredith et al. | Macrodosage of phenytoin | |
| Millichap | CNS Irradiation Effects on Puberty and Growth | |
| SOPHIAN | Spinal Analgesia in Eclampsia |